Equity Issuances

Ocean Capital Acquisition Corp issued an aggregate of 150,000 units of unit to the Sponsor for $10.00 per Private Placement Unit for an aggregate purchase price of $1,500,000.

“Simultaneously with the closing of the IPO, pursuant to the Sponsor Private Placement Units Purchase Agreement, the Company completed the private sale of an aggregate of 150,000 units (the “Private Placement Units”) to the Sponsor at a price of $10.00 per Private Placement Unit for an aggregate purchase price of $1,500,000.”

ERock, Inc. issued 171,226,057 shares of common stock to pre-IPO holders of units of ER Holdings.

“171,226,057 shares of the Company’s Class B common stock, $0.01 par value per share (the “ Class B Common Stock ”), to certain pre-IPO holders of units of ER Holdings”

ERock, Inc. issued 20,267,046 shares of common stock to pre-IPO holders of units of ER Holdings.

“20,267,046 shares of the Company’s Class A Common Stock to certain pre-IPO holders of units of ER Holdings”

Digital Brands Group, Inc. issued convertible note to 1800 Diagonal Lending, LLC for conversion price equal to 61% of the lowest closing bid price.

“Upon the occurrence of any event of default under the Note, (i) the Note will become immediately due and payable in an amount equal to 150% times the outstanding principal and accrued interest under the Note plus default interest at the rate of twenty-two percent (22%) per annum (the “Default Amount”), and (ii) 1800 Diagonal will have the right to convert the balance owed under the Note, including the Default Amount, into shares of common stock of the Company (“Common Stock”) at a conversion price equal to 61% of the lowest closing bid price during the ten trading days prior to the conversion date.”

Caro Holdings Inc. issued 20,000,000 shares of the Company's common stock of common stock to Goldrange Resources Corp..

“The 20,000,000 shares to be issued to Goldrange pursuant to the Agreement will be issued in a transaction exempt from registration under the Securities Act of 1933, as amended, in reliance on the exemption provided by Section 4(a)(2) thereof.”

JAB Acquisition Corp I issued 260,000 units of unit to the Sponsor for $2,600,000.

“the Company consummated a private placement (the “Private Placement”) of an aggregate of 260,000 units (the “Private Units”) to the Sponsor, at a price of $10.00 per Private Unit, generating total proceeds of $2,600,000.”

Sadot Group Inc. issued 132,803 shares of common stock to Anat Attia (as grantor) for $7.85 per share, aggregate value of $1,042,503.55.

“4, 2026; (ii) provides that Option Fee Tranche 1 is payable in shares of the Company’s Common Stock priced at the agreed five-day volume-weighted average price (“5-Day VWAP”) of $7.85 per share, as described under Item 3.02 below; (iii) replaces all references in the Option Agreement to preferred shares convertible into Common Stock with shares of the Company’s”

Edible Garden AG Inc issued 865,903 shares of the Company's common stock of common stock to Streeterville Capital, LLC for aggregate stated value of $199,000.

“the Company agreed to exchange 74 and 125 shares, respectively, of the Company’s Series B Preferred Stock, par value $0.0001 per share (the “Preferred Stock”), for a total of 865,903 shares of the Company’s common stock, par value $0.0001 per share (“Exchange Shares”). The Preferred Stock had an aggregate stated value of $199,000 (the “Stated Value”), or $1,000 per share.”

Snow Rothschild Acquisition Corp. issued 2,250,000 warrants of warrant to Snow Rothschild Acquisition Sponsor LLC (the Sponsor) for at a price of $1.00 per warrant, or $2,250,000 in the aggregate.

“Simultaneously with the closing of the IPO, pursuant to the Private Placement Warrants Purchase Agreement, the Company completed the private sale of an aggregate of 2,250,000 warrants (the “Private Placement Warrants”) to the Sponsor, with each warrant exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per warrant, or $2,250,000 in the aggregate.”

Nexentis Technologies Inc. issued 311,876 warrants to purchase up to 311,876 shares of warrant to same investors for aggregate gross proceeds of approximately $1.25 million.

“warranties, indemnification and other provisions customary for transactions of this nature. Aggregate gross proceeds to the Company in respect of the Offerings is approximately $1.25 million, before deducting offering expenses payable by the Company. The Offerings are expected to close on or about June 15, 2026, subject to satisfaction of customary closing”

Nexentis Technologies Inc. issued 311,876 of common stock to certain investors for aggregate gross proceeds of approximately $1.25 million.

“warranties, indemnification and other provisions customary for transactions of this nature. Aggregate gross proceeds to the Company in respect of the Offerings is approximately $1.25 million, before deducting offering expenses payable by the Company. The Offerings are expected to close on or about June 15, 2026, subject to satisfaction of customary closing”

Avalo Therapeutics, Inc. issued 4,294.675 shares of preferred stock to an accredited investor.

“On June 11, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with an accredited investor to exchange 4,294.675 outstanding shares of the Company’s outstanding Series C non-voting convertible preferred stock, $0.001 par value per share (the “Series C Preferred Stock”) for 4,294.675 shares of the Company’s newly created Series C-1 non-voting convertible preferred stock, $0.001 par value per share (the “Series C-1 Preferred Stock”), such exchange, the “Exchange”.”

Translational Development Acquisition Corp. issued 4,657,499 Class A ordinary shares of common stock to TDAC Partners LLC (the Sponsor) for no cash proceeds to the Company.

“On June 12, 2026, Translational Development Acquisition Corp., a Cayman Islands exempted company (the “Company”), issued an aggregate of 4,657,499 Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”), to TDAC Partners LLC (the “Sponsor”), upon the conversion (the “Conversion”) of an equal number of Class B ordinary shares, par value $0.0001 per share (the “Class B Ordinary Shares”), held by the Sponsor.”

Aeries Technology, Inc. issued warrant.

“the Company notified Warrant holders that the Company has made the following adjustments to its outstanding Warrants, effective after the close of trading on June 11, 2026, as reflected in the Warrants upon the commencement of trading on June 12, 2026”

APPlife Digital Solutions Inc issued common stock.

“On May 22, 2026, the Board of Directors (the “Board”) of APPlife Digital Solutions, Inc. (the “Company”) approved a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio of one-for-two hundred fifty (1-for-250)”

XCF Global, Inc. issued 233,333 shares of its Common Stock of common stock to H.C. Wainwright & Co., LLC for in lieu of cash fee of 7% of aggregate gross proceeds.

“the Company entered into an engagement letter with H.C. Wainwright & Co., LLC (" Wainwright "), pursuant to which it agreed to pay a cash fee of 7% of the aggregate gross proceeds raised in the offering, in lieu of which cash fee the Company agreed to issue to the placement agents an aggregate of 233,333 shares of its Common Stock.”

XCF Global, Inc. issued 666,666 of the Shares of common stock to existing stockholder for gross proceeds of $100,000.

“An existing stockholder of the Company will purchase directly from us 666,666 of the Shares for gross proceeds of $100,000.”

XCF Global, Inc. issued warrants to purchase common stock of the Company equal to 3% of the aggregate number of shares of common stock sold in the offering of warrant to placement agents (H.C. Wainwright & Co. and Roth Capital Partners) for engagement letter with cash fee of 7% of aggregate gross proceeds and reimbursement of legal fees.

“In connection with the offering, the Company entered into an engagement letter with H.C. Wainwright & Co., LLC (“ Wainwright ”), pursuant to which it agreed to pay a cash fee of 7% of the aggregate gross proceeds raised in the offering, in lieu of which cash fee the Company agreed to issue to the placement agents an aggregate of 233,333 shares of its”

XCF Global, Inc. issued aggregate of 4,000,000 shares of common stock to certain accredited investors for aggregate gross proceeds of approximately $600,000.00 at a purchase price per share of $0.15.

“On June 11, 2026, XCF Global, Inc. (the " Company "), entered into securities purchase agreements with certain accredited investors (the " Purchase Agreement ") pursuant to which the Company agreed to issue an aggregate of 4,000,000 shares (the " Shares ") of its Class A common stock, par value $0.0001 (" Common Stock ") for aggregate gross proceeds of approximately $600,000.00 at a purchase price per share of $0.15.”

SMITH MICRO SOFTWARE, INC. issued up to an aggregate of 487,349 shares of Common Stock of warrant to certain holders of existing Common Warrants for reduced exercise price of $3.35 per share in consideration for the Company's agreement to issue new unregistered Common Stock warrants to purchase up an aggrega.

“the Holders agreed to exercise the Warrants for cash at a reduced exercise price of $3.35 per share in consideration for the Company’s agreement to issue new unregistered Common Stock warrants to purchase up an aggregate of 487,349 shares of Common Stock at an exercise price of $3.80 per share (the “Inducement Transaction”)”

SharonAI Holdings Inc. issued 7,649,523 shares of its Class A Ordinary Common Stock of common stock to the Noteholders for conversion of an aggregate principal amount of approximately US$97,475,184 of unsecured, redeemable, convertible notes (the "Notes"), together with US$1,954,845.

“On June 11, 2026, SharonAI Holdings Inc. (the “Company”) issued 7,649,523 shares of its Class A Ordinary Common Stock, par value $0.0001 per share (the “Conversion Shares”) upon conversion of an aggregate principal amount of approximately US$97,475,184 of unsecured, redeemable, convertible notes (the “Notes”), together with US$1,954,845 of accrued and unpaid interest thereon pursuant to the terms of that certain Convertible Note Agreement (the “Agreement”), dated December 19, 2025, by and among SharonAI, Inc., SharonAI Pty Ltd and certain investors (the “Noteholders”)”

NEONC TECHNOLOGIES HOLDINGS, INC. issued up to 6,000 shares of preferred stock to certain accredited investors for $833.34 per share.

“of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) in a private placement. The Series A Preferred Stock will be issued at a purchase price of $833.34 per share, with up to 6,000 shares authorized for issuance. The transactions contemplated by the Purchase Agreement are expected to close upon the satisfaction of customary”

Crypto Co issued 96,000,000 shares of common stock of common stock to Three Mile Creek Future LLC, Bryn Rodriguez, and Ron Levy for aggregate purchase price of $300,000 in cash.

“On June 6, 2026 and June 11, 2026, The Crypto Company (the “ Company ”) executed Subscription Agreements (each, a “ Subscription Agreement ” and collectively, the “ Subscription Agreements ”) with certain institutional and other accredited investors: Three Mile Creek Future LLC, Bryn Rodriguez, and Ron Levy (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell and issue to the Investors an aggregate of 96,000,000 shares of the Company’s common stock, par value $0.001 (“ Common Stock ”) for an aggregate purchase price of $300,000 in cash, in a private placement transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) promulgated thereunder.”

VEEA INC. issued 1,765,296 Share Issuance Shares of common stock to four existing investors (Share Issuance Investors).

“On June 8, 2026, the Company issued to the Share Issuance Investors an aggregate of 1,765,296 Share Issuance Shares.”

VEEA INC. issued 1,891,388 shares of Common Stock of common stock to two existing investors (Note Conversion Investors) for aggregate of $750,000 in principal and accrued interest.

“On June 8, 2026, Notes having an aggregate of $750,000 in principal and accrued interest were converted into 1,891,388 shares of Common Stock (the “ Conversion Shares ”).”

RMG ML Sports Holdings issued 210,000 Units of unit to RMG ML Sports Holdings Sponsor LLC for at a purchase price of $10.00 per Private Placement Unit, generating gross proceeds to the Company of $2,100,000.

“On June 9, 2026, simultaneously with the closing of the IPO, pursuant to the Private Placement Unit Purchase Agreement, the Company completed the private sale of an aggregate of 210,000 Units (the “ Private Placement Units ”) to the Sponsor at a purchase price of $10.00 per Private Placement Unit, generating gross proceeds to the Company of $2,100,000.”

CIENA CORP issued 7,700,978 shares of common stock maximum of warrant to option counterparties for proceeds from warrant transactions.

“The Company sold the warrants comprising the warrant transactions described above to the option counterparties in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.”

AIM ImmunoTech Inc. issued 306,494 shares of Common Stock of warrant to Ladenburg Thalmann & Co. Inc..

“The Company also agreed to issue to the Placement Agent warrants (the “Placement Agent Warrants”) to purchase 306,494 shares of Common Stock (the “Placement Agent Warrant Shares”)”

AIM ImmunoTech Inc. issued up to 10,216,476 shares of Common Stock of warrant to institutional investors.

“Class J warrants (the “Class J Warrants”) to purchase up to 10,216,476 shares of Common Stock (the “Class J Warrant Shares”), at an exercise price of $0.5189 per share”

AIM ImmunoTech Inc. issued up to 1,782,616 shares of Common Stock of warrant to institutional investors.

“pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1,782,616 shares of Common Stock (the “Pre-Funded Warrant Shares”) at an exercise price of $0.001”

AIM ImmunoTech Inc. issued 771,503 shares of common stock to institutional investors for $0.5189 per share.

“the Company also agreed to issue and sell to such Investors, in a concurrent private placement, 771,503 shares of Common Stock at a per share price of $0.5189 (the “Unregistered Shares”)”

Parabilis Medicines, Inc. issued 4,166,666 shares of common stock to Regeneron Pharmaceuticals, Inc. for per share price equal to 90% of the initial public offering ("IPO") price of $20.00 per share.

“On June 9, 2026, Parabilis Medicines, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”), for the purchase of an aggregate of 4,166,666 shares (the “Shares”) of its voting common stock, par value $0.0001 (“Common Stock”), at a per share price equal to 90% of the initial public offering (“IPO”) price of $20.00 per share, through a private placement financing (the “Private Placement”), which took place concurrently with the IPO of the Company’s Common Stock. The Private Placement closed on June 11, 2026.”

VSEE HEALTH, INC. issued 532,481 shares of common stock to YA II PN, LTD..

“issue to the Investor 532,481 shares of Common Stock, representing 1.00% of the Commitment Amount divided by the VWAP of the Common Stock during the Trading Day immediately prior to the Effective Date, as a commitment fee (the “Commitment Shares”).”

Cottonwood Communities, Inc. issued 285,768 shares of preferred stock to accredited investors for aggregate proceeds of $2,838,000.

“During the period from June 2, 2026 through June 10, 2026, we issued and sold 285,768 shares of Series A Convertible Preferred Stock in the Series A Convertible Private Offering and received aggregate proceeds of $2,838,000.”

eXp World Holdings, Inc. issued common stock.

“Each outstanding share of common stock, par value $0.00001 of the Company automatically converted into one outstanding share of common stock, par value $0.00001 of the Texas Corporation.”

ExchangeRight Income Fund issued 12,690 of common stock to accredited investors for $350,000.

“Rule 506(c) of Regulation D promulgated thereunder. The following table details the shares sold: Number of Gross Share Class Shares Sold Proceeds Class D Common Shares 12,690 $ 350,000 Forward-Looking Statements Certain statements contained in this Current Report on Form 8-K other than historical facts may be considered “forward-looking statements,” and, as”

Porch Group, Inc. issued 2,092,050 shares of common stock to Porticus Reinsurance Ltd. for aggregate purchase price of $14,999,998.50.

“On the Effective Date, the Reciprocal sold Porticus 2,092,050 shares (the “Shares”) of the Company’s common stock for an aggregate purchase price of $14,999,998.50.”

Edesa Biotech, Inc. issued an aggregate of 729,241 common shares of common stock to certain investors for aggregate purchase price of approximately $3.5 million.

“Pursuant to the Purchase Agreement, the Purchasers have agreed to purchase, for an aggregate purchase price of approximately $3.5 million, an aggregate of 729,241 common shares (“Shares”), without par value, at a purchase price of $4.69 per Share for Purchasers other than the Company’s Chief Executive Officer, and $5.21 per Share for the Company’s Chief Executive Officer.”

Jaguar Health, Inc. issued common stock to Institutional Investor.

“In consideration for the Institutional Investor’s execution and delivery of the ELOC Agreement, the Company agreed to issue to the Institutional Investor on the effective date of the ELOC Registration Statement (as defined hereunder) $800,000 worth of the Company’s Common Stock, valued at the VWAP Purchase Price as of such effective date (the “Commitment Shares”).”

Prairie Operating Co. issued number of shares issuable upon exercise of Anniversary Warrants reduced of warrant to High Trail for amendment of warrant terms without additional consideration.

“amend Section 4(w) of the Securities Purchase Agreement, dated as of March 24, 2025, between the Company and High Trail, as amended (the “Purchase Agreement”), to change the “Anniversary Warrant Issuance Date” from July 8, 2026 to August 7, 2026, and (ii) reduce the number of shares of Common Stock issuable upon exercise of the Anniversary Warrants (as defined in the Series F Certificate of Designation) from (1) a number of shares equal to the quotient of (A) 75% of the Stated Value (as defined in the Series F Certificate of Designation) of all Series F Preferred Stock held by such holder on July 8, 2026, divided by (B) the average of the 10 daily volume-weighted average per share trading prices of the Common Stock during the 10 trading days prior to the issuance date of the Anniversary Warrants, to (2) a number of shares equal to the quotient of (A) 65% of the Stated Value of all Series F Preferred Stock held by such holder on August 7, 2026, divided by (B) the average of the 10 daily”

Xeris Biopharma Holdings, Inc. issued common stock to certain holders (the "Noteholders") of its 8.00% Convertible Senior Notes due 2028 for approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company's common stock.

“On June 10, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders (the “Noteholders”) of its 8.00% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which the Noteholders have agreed to exchange (the “Exchange”) approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company’s common stock (the “Exchange Consideration”).”

PetVivo Holdings, Inc. issued 187,500 Units of unit to the investor for $0.80 per Unit, gross proceeds $150,000.

“On June 8, 2026, PetVivo Holdings, Inc. (the “Company,” “we,” or “us”), received gross proceeds of $150,000 pursuant to a partial exercise of the investor’s purchase option granted under that certain Subscription Agreement dated March 13, 2026 (the “Subscription Agreement”), for an aggregate investment to date of $1,150,000 in equity financing (the “Offering”). In connection with such partial exercise, the Company issued 187,500 Units at a purchase price of $0.80 per Unit, bringing the aggregate number of Units issued pursuant to the Offering to date to 1,437,500 Units.”

Macquarie Infrastructure Fund, L.P. issued 3,134,752.32 of unit to accredited investors and qualified purchasers for $ 89,500,000.

“On May 1, 2026, Macquarie Infrastructure Fund, L.P. (the “Fund”) sold unregistered limited partnership units (the “Units”) for aggregate consideration of approximately $89,550,000. The following table details the Units sold by the Fund: Number of Units Sold (1) Consideration Class I 1,807.20 $ 50,000 Class E 3,134,752.32 $ 89,500,000”

Macquarie Infrastructure Fund, L.P. issued 1,807.20 of unit to accredited investors and qualified purchasers for $ 50,000.

“On May 1, 2026, Macquarie Infrastructure Fund, L.P. (the “Fund”) sold unregistered limited partnership units (the “Units”) for aggregate consideration of approximately $89,550,000. The following table details the Units sold by the Fund: Number of Units Sold (1) Consideration Class I 1,807.20 $ 50,000”

Netcapital Inc. issued convertible note to Vanquish Funding Group Inc. for purchase price of $157,000.

“On June 5, 2026, Netcapital Inc. (the “Company”) entered into a Securities Purchase Agreement, dated June 4, 2026 (the “Purchase Agreement”), with Vanquish Funding Group Inc., a Virginia corporation (the “Buyer”), pursuant to which the Company issued to the Buyer a promissory note in the principal amount of $182,120 (the “Note”) for a purchase price of $157,000”

Dream Finders Homes, Inc. issued common stock.

“At the Effective Time, each outstanding share of Class A common stock, par value $0.01 per share, of the Delaware corporation (the “Delaware Corporation Class A common stock”) automatically converted into one outstanding share of Class A common stock, par value $0.01 per share, of the Texas corporation (the “Texas Corporation Class A common stock”), and each outstanding share of Class B common stock, par value $0.01 per share, of the Delaware corporation (the “Delaware Corporation Class B common stock”) automatically converted into one outstanding share of Class B common stock, par value $0.01 per share, of the Texas corporation.”

Syndax Pharmaceuticals Inc issued $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 of convertible note to certain investors for approximately $243.0 million net proceeds.

“(and the foregoing description is qualified in its entirety by reference to such documents). Proceeds The Company’s net proceeds from the Private Placement were approximately $243.0 million, after deducting the placement agent’s fees and Private Placement expenses payable by the Company. The Company expects to use the net proceeds from the Private Placement for”

Netcapital Inc. issued 125,000 shares of common stock of warrant to Labrys Fund II, L.P..

“and a common stock purchase warrant dated June 3, 2026 to purchase 125,000 shares of the Company’s common stock, par value $0.001 per share, at an initial exercise price of $0.50 per share”

Netcapital Inc. issued convertible note to Labrys Fund II, L.P. for $125,000 purchase price.

“and delivered to Labrys a promissory note dated June 3, 2026 in the principal amount of $145,000 (the “Note”) and a common stock purchase warrant dated June 3, 2026 to purchase 125,000 shares of the Company’s common stock, par value $0.001 per share, at an initial exercise price of $0.50 per share (the “Warrant,” and together with the Note, the shares issuable”

WhiteHawk Income Corp issued all outstanding shares of the Company’s Series D preferred stock of preferred stock for $1,000 per share.

“the Company redeemed all outstanding shares of the Company’s Series D preferred stock, par value $0.0001 per share (the “Series D Preferred Stock”). The Series D Preferred Stock was redeemed for $1,000 per share, plus all accrued but unpaid dividends thereon, if any, plus, if applicable, an additional amount such that each holder receives the Minimum Return (as defined in the Certificate of Designations of the Series D Preferred Stock), for an aggregate redemption amount of approximately $39.9 million (the “Series D Redemption”).”